{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:58:52Z","timestamp":1790276332457,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40262-018-0638-5","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T13:24:52Z","timestamp":1521120292000},"page":"1399-1405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens"],"prefix":"10.1007","volume":"57","author":[{"given":"Thomas","family":"T\u00e4ngd\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Cojutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"638_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/00003495-200565060-00012","volume":"5","author":"RS Cvetkovi\u0107","year":"2005","unstructured":"Cvetkovi\u0107 RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;5:859\u201378.","journal-title":"Drugs"},{"key":"638_CR2","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","volume":"340","author":"D Lowance","year":"1999","unstructured":"Lowance D, Neumayer HH, Legendre CM, et al. Valganciclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462\u201370.","journal-title":"N Engl J Med"},{"key":"638_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/00912709922008452","volume":"39","author":"D Jung","year":"1999","unstructured":"Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir agents for solid organ transplantation. J Clin Pharmacol. 1999;39:800\u20134.","journal-title":"J Clin Pharmacol"},{"key":"638_CR4","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","volume":"44","author":"MD Pescovitz","year":"2000","unstructured":"Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"638_CR5","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003495-200161080-00016","volume":"61","author":"JK McGavin","year":"2001","unstructured":"McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61:1153\u201383.","journal-title":"Drugs"},{"key":"638_CR6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","volume":"79","author":"H Wiltshire","year":"2005","unstructured":"Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477\u201383.","journal-title":"Transplantation"},{"key":"638_CR7","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1128\/AAC.00085-09","volume":"53","author":"A Cald\u00e9s","year":"2009","unstructured":"Cald\u00e9s A, Colom H, Armendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother. 2009;53:4816\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"638_CR8","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1128\/AAC.39.10.2350","volume":"39","author":"GJ Yuen","year":"1995","unstructured":"Yuen GJ, Drusano GL, Fletcher C, et al. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob Agents Chemother. 1995;39:2350\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"638_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","volume":"48","author":"N Perrottet","year":"2009","unstructured":"Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet. 2009;48:399\u2013418.","journal-title":"Clin Pharmacokinet"},{"key":"638_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0378-4347(91)80155-6","volume":"567","author":"R Boulieu","year":"1991","unstructured":"Boulieu R, Bleyzac N, Ferry S. High-performance liquid chromatographic determination of ganciclovir in plasma. J Chromatogr. 1991;567:481\u20134.","journal-title":"J Chromatogr"},{"key":"638_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10928-013-9302-8","volume":"40","author":"T Tatarinova","year":"2013","unstructured":"Tatarinova T, Neely M, Bartroff J, et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013;40:189\u201399.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"638_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"M Neely","year":"2012","unstructured":"Neely M, van Guilder M, Yamada W, Schumitzky A, Jelliffe R. Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467.","journal-title":"Ther Drug Monit"},{"key":"638_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"638_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens AL, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"638_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10928-005-0016-4","volume":"33","author":"F Mentr\u00e9","year":"2006","unstructured":"Mentr\u00e9 F, Escolano S. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn. 2006;33:345\u201367.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"638_CR16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1128\/AAC.02130-15","volume":"60","author":"A Padull\u00e9s","year":"2016","unstructured":"Padull\u00e9s A, Colom H, Bestard O, et al. Contribution of population pharmacokinetics to dose optimization of ganciclovir in solid organ transplant patients. Antimicrob Agents Chemother. 2016;60:1992\u20132002.","journal-title":"Antimicrob Agents Chemother"},{"key":"638_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bcp.12343","volume":"78","author":"H Vezina","year":"2014","unstructured":"Vezina H, Brundage RC, Balfour HH. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. Br J Clin Pharmacol. 2014;78:343\u201352.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0638-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:46:04Z","timestamp":1552610764000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0638-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0638-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"15 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by internal funding. We wish to recognise funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP1099452). JAR is funded in part by a Practitioner Fellowship (APP1117065) from the National Health and Medical Research Council of Australia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas T\u00e4ngd\u00e9n, Pier Giorgio Cojutti and Federico Pea declare no conflicts of interest. Jason A. Roberts has received investigator-initiated grants from, or has consulted for, bioM\u00e9rieux, Astellas, MSD and Cardeas Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}